Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Jimenez E, Astbury C, Albayaty M, Wählby-Hamrén U, Seoane B, Villarroel C, Pujol H, Bermejo MJ, Aggarwal A, Psallidas I. Jimenez E, et al. Among authors: aggarwal a. Respir Res. 2020 Sep 9;21(Suppl 1):211. doi: 10.1186/s12931-020-01470-5. Respir Res. 2020. PMID: 32907576 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D, Balaguer V, Astbury C, Wählby-Hamrén U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Singh D, et al. Among authors: aggarwal a. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7. Respir Res. 2020. PMID: 32907566 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Balaguer V, Albayaty M, Jimenez E, Wählby-Hamrén U, Astbury C, Seoane B, Malice MP, Lei A, Aggarwal A, Psallidas I. Balaguer V, et al. Among authors: aggarwal a. Respir Res. 2020 Sep 9;21(Suppl 1):212. doi: 10.1186/s12931-020-01474-1. Respir Res. 2020. PMID: 32907575 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers.
Prothon S, Wählby Hamrén U, Tehler U, Yoon E, Forsman H, Arfvidsson C, Aggarwal A, Chen Y. Prothon S, et al. Among authors: aggarwal a. Drug Des Devel Ther. 2019 Nov 12;13:3845-3853. doi: 10.2147/DDDT.S215170. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31814707 Free PMC article. Clinical Trial.
Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
Brown MN, Fuhr R, Beier J, Su HL, Chen Y, Forsman H, Hamrén UW, Jackson H, Aggarwal A. Brown MN, et al. Among authors: aggarwal a. Respir Res. 2019 Feb 18;20(1):37. doi: 10.1186/s12931-019-1000-7. Respir Res. 2019. PMID: 30777086 Free PMC article. Clinical Trial.
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
3,712 results